Neurogene Inc. (NGNE)
NASDAQ: NGNE · Real-Time Price · USD
20.28
-0.88 (-4.16%)
At close: Dec 5, 2025, 4:00 PM EST
20.26
-0.02 (-0.10%)
After-hours: Dec 5, 2025, 5:01 PM EST
Neurogene Employees
Neurogene had 107 employees as of December 31, 2024. The number of employees increased by 16 or 17.58% compared to the previous year.
Employees
107
Change (1Y)
16
Growth (1Y)
17.58%
Revenue / Employee
n/a
Profits / Employee
-$795,607
Market Cap
314.13M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 107 | 16 | 17.58% |
| Dec 31, 2023 | 91 | 9 | 10.98% |
| Dec 31, 2022 | 82 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
NGNE News
- 2 days ago - Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 12 days ago - Neurogene: From Speculation To Execution With NGN-401 - Seeking Alpha
- 23 days ago - Neurogene Reports Third Quarter 2025 Financial Results and Highlights Recent Updates - Business Wire
- 23 days ago - Neurogene Inc. (NGNE) Presents at Stifel 2025 Healthcare Conference Transcript - Seeking Alpha
- 24 days ago - Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome - Business Wire
- 4 weeks ago - Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome - Business Wire
- 4 weeks ago - Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Embolden™ Registrational Trial in Q4 2025 - Business Wire